Regorafenib in the treatment of metastatic colorectal cancer

A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis

(2018) Ana B.K. Abrahao et al.   Clinical Colorectal Cancer

Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link?

(2017) Fabiana Pani et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study

(2017) Salvatore Del Prete et al.   Future Oncology

Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study

(2017) Khurum Khan et al.   GUT

Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC–MS/MS

(2017) Marie Allard et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Recent developments in the treatment of metastatic colorectal cancer

(2017) Jonathan M. Loree et al.   Therapeutic Advances in Medical Oncology

611TiPADJUVANT REGORAFENIB (REG) IN STAGE IV COLORECTAL CANCER (CRC) AFTER CURATIVE TREATMENT OF LIVER METASTASES: A PHASE III RANDOMIZED, PLACEBO (PBO)-CONTROLLED TRIAL (COAST)

(2017) A. Grothey et al.   ANNALS OF ONCOLOGY

Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis

(2017) Riccardo Giampieri et al.   Scientific Reports

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

(2016) E. Van Cutsem et al.   ANNALS OF ONCOLOGY

Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program

(2016) Antoine Adenis et al.   BMC CANCER

Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer

(2016) Mitsukuni Suenaga et al.   Oncotarget

Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models

(2016) Dieter Zopf et al.   Cancer Medicine

LBA-05Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer

(2015) E. Van Cutsem et al.   ANNALS OF ONCOLOGY

Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial

(2015) Guillem Argilés et al.   EUROPEAN JOURNAL OF CANCER

Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib

(2015) Camille Tlemsani et al.   Expert Opinion on Drug Metabolism & Toxicology

Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Jin Li et al.   LANCET ONCOLOGY

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial

(2015) Josep Tabernero et al.   LANCET ONCOLOGY

Comment on: “Regorafenib: Start Low and Go Slow”

(2015) Christelle de la Fouchardière   Targeted Oncology

Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management.

(2015) Michela Del Prete et al.   Oncotarget

The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value

(2015) Xiaojun Jiang et al.   Oncotarget

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

(2014) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations

(2014) Takayuki Yoshino et al.   INVESTIGATIONAL NEW DRUGS

Optimizing Treatment Outcomes With Regorafenib: Personalized Dosing and Other Strategies to Support Patient Care

(2014) A. Grothey et al.   ONCOLOGIST

Regorafenib: start low and go slow

(2014) S. Tabchi et al.   Targeted Oncology

Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management

(2014) Gazala Khan et al.   Cancer Management and Research

Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study

(2013) B. Schultheis et al.   ANNALS OF ONCOLOGY

Prevention and management of adverse events related to regorafenib

(2013) Mieke De Wit et al.   SUPPORTIVE CARE IN CANCER

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

(2012) D Strumberg et al.   BRITISH JOURNAL OF CANCER

A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

(2012) K. Mross et al.   CLINICAL CANCER RESEARCH

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

(2010) Scott M. Wilhelm et al.   INTERNATIONAL JOURNAL OF CANCER